The drugmaker Merck is launching its previously-disclosed $8.4 billion offer to buy Cubist Pharmaceuticals shares in a deal that aims to strengthen its ability to treat serious infections, an issue drawing growing concern globally. Merck said earlier this month that it will pay $102 in cash for each share of Cubist, which represented a 37 percent premium to the stock's closing price before the deal was announced.